In recent years, probiotics have been used as a treatment to promote oral health, they have a fundamental role in keeping the balance of the microbial ecology associated with the ability of bacterial species to interfere during surface colonization. In the oral cavity, Streptococcus salivarius, a non-pathogenic and predominant oral species, is able to coexist in the same environment and reduce the frequency of colonization of the main pathogens involved in upper respiratory tract infections. The aim of the present study was to test the safety, tolerability and the rhinopharynx colonization of S. salivarius 24 SMB already studied for its characterized to be not virulence, not antibiotic resistance, ability to inhibit S. pneumoniae and S. pyogenes, and efficient adhesion in vitro. characterize oral bacteria for use as potential probiotics in the prevention and/or treatment of URTIs including chronic and/or acute otitis media. We found one strain, S. salivarius 24 SMB, by screening 13 BLIS oral streptococci isolated from nasal and/or pharyngeal swabs of thirty-one healthy children aged between two and twelve years. S. salivarius 24 SMB shows promising properties for its use as an oral probiotic: safety assessment. In addition, the clinical trial protocol ( protocollo di sperimentazione clinica) conducted on eight healthy volunteers to evaluate the safety and the ability to colonize and persistence of upper respiratory tract infections of a nasal spray formulation of S. salivarius 24 SMB has demonstrated: i) the absence of adverse effects for all subjects enrolled and ii) the capability of S. salivarius 24 SMB to persist in rhinopharynx infections in 6 subjects also after 6 days from the last dose of formulation. This result was obtained by analysis of each colony of S.salivarius isolated after treatment using antagonism tests to evaluate BLIS production and RAPD-PCR to distinguish S. salivarius 24 SMB’s genotype from other S.salivarius strains. Thus, S. salivarius 24 SMB possesses the potential as an oral probiotic in the prevention and/or treatment of URTIs including chronic and/or acute otitis media.

Bacterio-Therapy In Human Rhinopharynx: An Update.

SANTAGATI, Maria Carmela;LA MANTIA, Ignazio;
2012

Abstract

In recent years, probiotics have been used as a treatment to promote oral health, they have a fundamental role in keeping the balance of the microbial ecology associated with the ability of bacterial species to interfere during surface colonization. In the oral cavity, Streptococcus salivarius, a non-pathogenic and predominant oral species, is able to coexist in the same environment and reduce the frequency of colonization of the main pathogens involved in upper respiratory tract infections. The aim of the present study was to test the safety, tolerability and the rhinopharynx colonization of S. salivarius 24 SMB already studied for its characterized to be not virulence, not antibiotic resistance, ability to inhibit S. pneumoniae and S. pyogenes, and efficient adhesion in vitro. characterize oral bacteria for use as potential probiotics in the prevention and/or treatment of URTIs including chronic and/or acute otitis media. We found one strain, S. salivarius 24 SMB, by screening 13 BLIS oral streptococci isolated from nasal and/or pharyngeal swabs of thirty-one healthy children aged between two and twelve years. S. salivarius 24 SMB shows promising properties for its use as an oral probiotic: safety assessment. In addition, the clinical trial protocol ( protocollo di sperimentazione clinica) conducted on eight healthy volunteers to evaluate the safety and the ability to colonize and persistence of upper respiratory tract infections of a nasal spray formulation of S. salivarius 24 SMB has demonstrated: i) the absence of adverse effects for all subjects enrolled and ii) the capability of S. salivarius 24 SMB to persist in rhinopharynx infections in 6 subjects also after 6 days from the last dose of formulation. This result was obtained by analysis of each colony of S.salivarius isolated after treatment using antagonism tests to evaluate BLIS production and RAPD-PCR to distinguish S. salivarius 24 SMB’s genotype from other S.salivarius strains. Thus, S. salivarius 24 SMB possesses the potential as an oral probiotic in the prevention and/or treatment of URTIs including chronic and/or acute otitis media.
Bacterio-Therapy ; bacteriocins; Streptococcus salivarius
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/97572
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact